This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogen
This SERPINA4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 291-320 amino acids from the C-terminal region of human SERPINA4.
SERPINA4
Reaktivität: Maus
WB, IF (cc), IF (p)
Wirt: Kaninchen
Polyclonal
AbBy Fluor® 350
Applikationshinweise
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
For FACS starting dilution is: 1:10~50
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
2 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
SERPINA4
(serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 4 (SERPINA4))
KLKR antikoerper, Klk6 antikoerper, hK1 antikoerper, KAL antikoerper, KLST antikoerper, KST antikoerper, PI-4 antikoerper, PI4 antikoerper, kallistatin antikoerper, SERPINA4 antikoerper, DKFZp469E1737 antikoerper, KALps antikoerper, Klst antikoerper, kallikrein 1 antikoerper, serpin family A member 4 antikoerper, serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 antikoerper, serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1 antikoerper, KLK1 antikoerper, SERPINA4 antikoerper, Serpina4 antikoerper, SPIA4 antikoerper, Serpina4-ps1 antikoerper
Hintergrund
SERPINA4 inhibits human amidolytic and kininogenase activities of tissue kallikrein. The inhibition is achieved by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and generation of a small C-terminal fragment of the inhibitor due to cleavage at the reactive site by tissue kallikrein.